PPARs: therapeutic targets for metabolic disease

被引：586

作者：

Berger, JP ^{[1
]}

Akiyama, TE

Meinke, PT

机构：

[1] Merck Res Labs, Dept Metab Disorders, Rahway, NJ 07065 USA

[2] Merck Res Labs, Dept Med Chem, Rahway, NJ 07065 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2005年 / 26卷 / 05期

关键词：

D O I：

10.1016/j.tips.2005.03.003

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The three peroxisome-proliferator-activated receptor (PPAR) subtypes, PPAR-gamma, PPAR-alpha and PPAR-delta, are nuclear receptors that have been the focus of extensive research during the past decade. These receptors function as lipid sensors that coordinately regulate the expression of large gene arrays and, thereby, modulate important metabolic events. They are also the targets of drugs that are effective in the treatment of metabolic disorders (type 2 diabetes mellitus and atherosclerosis) that afflict industrialized societies at epidemic levels. Ongoing research indicates that modulation of PPAR activity might be an effective therapy for additional maladies associated with the metabolic syndrome, including obesity. Novel PPAR ligands are now being developed that possess broader efficacies and improved tolerability compared with currently available therapeutic agents.

引用

页码：244 / 251

页数：8

共 87 条

[1] Benzoyl 2-methyl indoles as selective PPARγ modulators [J].

Acton, JJ ;

Black, RM ;

Jones, AB ;

Moller, DE ;

Colwell, L ;

Doebber, TW ;

MacNaul, KL ;

Berger, J ;

Wood, HB .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2005, 15 (02) :357-362

[2] Conditional disruption of the peroxisome proliferator-activated receptor γ gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux [J].

Akiyama, TE ;

Sakai, S ;

Lambert, G ;

Nicol, CJ ;

Matsusue, K ;

Pimprale, S ;

Lee, YH ;

Ricote, M ;

Glass, CK ;

Brewer, HB ;

Gonzalez, FJ .

MOLECULAR AND CELLULAR BIOLOGY, 2002, 22 (08) :2607-2619

[3] An antidiabetic thiazolidinedione induces eccentric cardiac hypertrophy by cardiac volume overload in rats [J].

Arakawa, K ;

Ishihara, T ;

Aoto, M ;

Inamasu, M ;

Kitamura, K ;

Saito, A .

CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2004, 31 (1-2) :8-13

[4] Regional adipocity in man [J].

Arner, P .

JOURNAL OF ENDOCRINOLOGY, 1997, 155 (02) :191-192

[5] Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients [J].

Bajaj, M ;

Suraamornkul, S ;

Piper, P ;

Hardies, LJ ;

Glass, L ;

Cersosimo, E ;

Pratipanawatr, T ;

Miyazaki, Y ;

Defronzo, RA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (01) :200-206

[6] Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes [J].

Bajaj, M ;

Suraamornkul, S ;

Pratipanawatr, T ;

Hardies, LJ ;

Pratipanawatr, W ;

Glass, L ;

Cersosimo, E ;

Miyazaki, Y ;

DeFronzo, RA .

DIABETES, 2003, 52 (06) :1364-1370

[7] PPARγ is required for placental, cardiac, and adipose tissue development [J].

Barak, Y ;

Nelson, MC ;

Ong, ES ;

Jones, YZ ;

Ruiz-Lozano, P ;

Chien, KR ;

Koder, A ;

Evans, RM .

MOLECULAR CELL, 1999, 4 (04) :585-595

[8] Pharmacotherapy for dyslipidaemia - current therapies and future agents [J].

Bays, H ;

Stein, EA .

EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (11) :1901-1938

[9] Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: Peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach [J].

Bays, H ;

Mandarino, L ;

DeFronzo, RA .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2004, 89 (02) :463-478

[10] The adipocyte-secreted protein Acrp30 enhances hepatic insulin action [J].

Berg, AH ;

Combs, TP ;

Du, XL ;

Brownlee, M ;

Scherer, PE .

NATURE MEDICINE, 2001, 7 (08) :947-953

← 1 2 3 4 5 6 7 8 9 →